Metcela Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$14M
- Investors
-
22
Metcela General Information
Description
Developer of a regenerative medicine therapy designed to treat congenital heart disease and rare conditions. The company offers innovative cell-based pharmaceuticals developed through advanced research in cardiac regeneration, enabling pediatric and rare disease patients to access transformative treatments that restore heart function and improve quality of life.
Contact Information
Website
www.metcela.comCorporate Office
- 3-25-22 Tonomachi
- Kawasaki-ku, Kanagawa
- Kawasaki, Kanagawa 210-0821
- Japan
Corporate Office
- 3-25-22 Tonomachi
- Kawasaki-ku, Kanagawa
- Kawasaki, Kanagawa 210-0821
- Japan
Metcela Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Later Stage VC (Series C) | 28-Jun-2022 | $14M | Completed | Pre-Clinical Trials | ||
| 11. Later Stage VC (Series B) | 24-Feb-2021 | Completed | Pre-Clinical Trials | |||
| 10. Accelerator/Incubator | 08-Jul-2019 | Completed | Pre-Clinical Trials | |||
| 9. Early Stage VC (Series A) | 30-Aug-2018 | Completed | Pre-Clinical Trials | |||
| 8. Grant | 01-Jul-2018 | Completed | Pre-Clinical Trials | |||
| 7. Accelerator/Incubator | 01-Jan-2018 | Completed | Pre-Clinical Trials | |||
| 6. Accelerator/Incubator | 01-Jan-2018 | Completed | Pre-Clinical Trials | |||
| 5. Grant | 01-Mar-2017 | Completed | Pre-Clinical Trials | |||
| 4. Accelerator/Incubator | 01-Jan-2017 | $1.37M | Completed | Pre-Clinical Trials | ||
| 3. Accelerator/Incubator | $1.37M | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Metcela Comparisons
Industry
Financing
Details
Metcela Competitors (43)
One of Metcela’s 43 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Cellaion | Formerly VC-backed | Mont-Saint-Guibert, Belgium | ||||
| WaVe Life Sciences | Formerly VC-backed | Cambridge, MA | ||||
| Skyhawk Therapeutics | Venture Capital-Backed | Waltham, MA | ||||
| Cardurion | Venture Capital-Backed | Burlington, MA |
Metcela Patents
Metcela Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4671364-A1 | Cell population containing cardiac stem cells | Pending | 24-Feb-2023 | ||
| JP-2024120546-A | Cell population containing cardiac stem cells | Active | 24-Feb-2023 | ||
| WO-2024176514-A1 | Cell population containing cardiac stem cells | Inactive | 24-Feb-2023 | ||
| JP-7373246-B1 | Cell populations including cardiac stem cells | Active | 24-Feb-2023 | ||
| CA-3226199-A1 | Fibroblast-containing pharmaceutical composition for treating kidney disease | Pending | 08-Sep-2021 | A61K35/33 |
Metcela Signals
Metcela Investors (22)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cyberdyne | Corporation | Minority | ||
| Reazon Capital | Venture Capital | Minority | ||
| Reazon Holdings | Holding Company | Minority | ||
| TOHOKU University Venture Partners | Venture Capital | Minority | ||
| Alfresa Holdings | Corporation | Minority |
Metcela Acquisitions (1)
Metcela’s most recent deal was a Merger/Acquisition with Japan Regenerative Medicine. The deal was made on 04-Apr-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Japan Regenerative Medicine | 04-Apr-2022 | Merger/Acquisition | Biotechnology |
Metcela FAQs
-
When was Metcela founded?
Metcela was founded in 2016.
-
Where is Metcela headquartered?
Metcela is headquartered in Kawasaki, Japan.
-
What is the size of Metcela?
Metcela has 20 total employees.
-
What industry is Metcela in?
Metcela’s primary industry is Drug Discovery.
-
Is Metcela a private or public company?
Metcela is a Private company.
-
What is Metcela’s current revenue?
The current revenue for Metcela is .
-
How much funding has Metcela raised over time?
Metcela has raised $32.9M.
-
Who are Metcela’s investors?
Cyberdyne, Reazon Capital, Reazon Holdings, TOHOKU University Venture Partners, and Alfresa Holdings are 5 of 22 investors who have invested in Metcela.
-
Who are Metcela’s competitors?
Inovio Pharmaceuticals, Cellaion, WaVe Life Sciences, Skyhawk Therapeutics, and Cardurion are some of the 43 competitors of Metcela.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process